Treatment-associated phenotype switching between psoriasis and atopic dermatitis - PubMed
2 hours ago
- #JAK inhibitors
- #biologic therapy
- #phenotype switching
- Treatment-associated phenotype switching between psoriasis and atopic dermatitis is a bidirectional phenomenon.
- Switching involves psoriasis patients developing eczematous features or AD patients developing psoriasiform lesions.
- Switches in psoriasis primarily occur with IL-17 and IL-23 inhibitor therapies.
- Switches in AD occur exclusively during biologic therapies targeting type 2 inflammation, especially dupilumab.
- Janus kinase (JAK) inhibitors were commonly used after switching and led to marked clinical improvement.
- The phenomenon reflects immune plasticity rather than paradoxical disease induction.
- Recognition is essential for guiding therapeutic adaptation and optimizing management.